Drug Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name SBI-0206965
Trade Name
Drug Descriptions

SBI-0206965 is a small molecule that selectively inhibits ULK1, resulting in decreased phosphorylation of ULK1 targets, and potentially leading to increased tumor cell death in combination with mTOR inhibitors (PMID: 26118643, PMID: 30166400, PMID: 32393312).



  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
AZD8055 + SBI-0206965 AZD8055 SBI-0206965 1 0
Cabozantinib + SBI-0206965 Cabozantinib SBI-0206965 1 0
Crizotinib + SBI-0206965 Crizotinib SBI-0206965 1 0
Regorafenib + SBI-0206965 Regorafenib SBI-0206965 1 0
Sapanisertib + SBI-0206965 SBI-0206965 Sapanisertib 1 0
SBI-0206965 SBI-0206965 0 0
SBI-0206965 + Sirolimus SBI-0206965 Sirolimus 1 0

Additional content available in CKB BOOST